Stay updated on Fostamatinib Comb-Paclitaxel in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Fostamatinib Comb-Paclitaxel in Ovarian Cancer Clinical Trial page.

Latest updates to the Fostamatinib Comb-Paclitaxel in Ovarian Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedOvarian cancer and the related MedlinePlus Genetics topic were removed from the page. This reduces the core context for the study.SummaryDifference0.2%

- Check15 days agoChange DetectedThe Locations section now lists District of Columbia, Maryland, and Pennsylvania as study sites, with Revision: v3.3.3.SummaryDifference0.4%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedAdded related topic tags: Ovarian cancer and MedlinePlus Genetics to the study page. These changes are metadata and do not alter the trial details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check37 days agoChange DetectedRemoved the 'Ovarian Cancer' topic tag and related topics such as MedlinePlus Genetics from the study page. This affects the page’s categorization and discoverability for users searching by disease.SummaryDifference0.2%

- Check44 days agoChange DetectedThe page shows a minor revision update from v3.2.0 to v3.3.2 with no observable changes to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedRemoved the government funding/operating status notice banner from the page.SummaryDifference0.4%

Stay in the know with updates to Fostamatinib Comb-Paclitaxel in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fostamatinib Comb-Paclitaxel in Ovarian Cancer Clinical Trial page.